CTLA4 and neoplasm: The CIAO trial evaluated durvalumab (anti-PD-L1) with or without tremelimumab (anti-CTLA-4) in 28 patients prior to surgery, with 29% showing tumor reduction to 10% of the pretreatment volume and 25% showing downstaging of the tumor [30].